The Ministry of Health will procure the innovative medication Trikafta for patients with cystic fibrosis, following the signing of an agreement with the drug’s manufacturer, US biopharmaceutical company Vertex Pharmaceuticals. The relevant statement made today the Minister of Health.

“The medication is authorised by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for patients aged 2 and over with genetic mutations, matching the approved indications.

The drug acts directly on the underlying genetic cause of the disease, delivering a marked improvement in lung function indicators and arresting progressive damage. As a result, the risk of infectious complications, the need for hospitalisation, and the necessity of lung transplantation are substantially reduced.

The innovative therapy directly acts on the genetic defect causing the disease and significantly improves lung function metrics in patients.

The treatment also substantially reduces the frequency of pulmonary exacerbations and the need for hospitalization. As a result of the joint efforts of the state and parents, a contract was signed today with the company “Vertex”, according to which the state will purchase the gene modulator known as “Trikafta”.

I would also like to express my deep gratitude to the Government of Georgia and personally to the Prime Minister of Georgia for this decision and for fully supporting the process. From today, work on introducing the medication will continue, which we will carry out in ongoing active cooperation with the parents. In reality, we will begin the process of supplying the medication in September”, - said Mukheil Sarjveladze.

Cystic fibrosis is a progressive genetic condition that typically manifests in childhood, primarily affecting the lungs and digestive system. Respiratory infections are frequent, and over time, pulmonary function and overall health deteriorate significantly.

The need for continuous treatment and the limitations imposed by the illness place a considerable burden on children’s daily lives and development; consequently, access to modern therapy is of paramount importance. In September 2025, Trikafta was added to the World Health Organisation’s Model List of Essential Medicines, confirming its critical role in contemporary cystic fibrosis treatment.